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PROPRANOLOL-RESISTANT INFANTILE HEMANGIOMAS: 
THE ANALYSIS OF 2 CASES 
Ovechkin D. V., Leonov V.V., Ngetich E., Adigun Z. 
Sumy State University, Department of Surgery with Children Surgery and Course of Urology 
 Infantile hemangiomas (IH) are the most common soft-tissue tumours of infancy. Although 
propranolol has been shown to treat IH effectively, there are a few cases of propranolol-resistant IH 
(PRIH) are mentioned in the literature. The incidence of PRIH in different studies is 0-9%.  
The objective of this study is to describe and analyze the clinical cases of PRIH. 
This prospective study was conducted in the department of Pediatric surgery at Sumy 
Region Children's Clinical Hospital (Ukraine) between September 2012 and January 2016. 
The patient’s mean age at initiation of propranolol therapy was 2.5 months (1-18 months). 
Propranolol was given to 44 cases: 40 – proliferative stage of IH; 4 – non-proliferative stage. 
Congenital hemangiomas were not included to this study.  
Propranolol was prescribed in dose of 1-3 mg/kg per day orally at 8-hour interval. 
PRIH was described as continued growth of IH during the proliferation stage or no IH reduction 
during the post-proliferative stage after at least 4 weeks of propranolol therapy in dose ≥ 2 mg/kg 
per day.  
All patients tolerated to propranolol well without side effects. PRIH was confirmed in 2 
patients – 4,5% (2/44). The increasing a dose of propranolol to 3 mg/kg per day at 8-hour interval 
have not removed the resistance to therapy.  Patient’s data with PRIH are summarized.  
Case # 1: sex – girl; gestational age – 39 weeks; birth weight – 3150 kg; IH localization – 
cheek; age of lesions onset – 1 week; IH complications – ulceration; IH stage – proliferative; age of 
initial treatment – 3 week; duration of maximum dose (3 mg/kg/d) – 6 month; total duration of 
propranolol therapy – 6 month. 
Case # 2: sex – girl; gestational age – 40 weeks; birth weight – 3500 kg; IH localization – 
trunk; age of lesions onset – 3 week; IH complications – ulceration and infection; IH stage – 
proliferative; age of initial treatment – 2 week; duration of maximum dose (3 mg/kg/d) – 6 month; 
total duration of propranolol therapy – 6 month. 
Adjuvant therapy was prescribed to both patients with PRIH (prednisolone, 2 mg/kg/d, 
orally). We observed that the use of systemic corticosteroid was effective. 
Conclusion 
In our study the PRIH is 4,5% of all propranolol therapy patients; however this type of 
lesions required more clinical studies to determine their nature and optimal treatment. 
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Gastric cancer (CG) has been described as early as 3000 BC in hieroglyphic inscriptions and 
papyri manuscripts from ancient Egypt. The first major statistical analysis of cancer incidence and 
mortality showed that GC was the most common and lethal cancer. It has remained one of the most 
important malignant diseases with significant geographical, ethnic, and socioeconomic differences 
in distribution. 
Aim: to retrospectively assess the differences of GC between the African and European 
population.  
Methods and Material:  A retrospective study of histologically confirmed cases of gastric 
cancer seen at Bugando Medical Centre  and epidemiological studies of Ukraine National Cancer 
Registry 
Results:Tanzania ranking is No.141 worldwide with a ratio of 2.97 per 100,000 cancer 
patients.A total of 232 GC patients were enrolled in the study, representing 4.5% of all 
malignancies. The male to female ratio was 2.9:1. The median age of patients was 52 years. The 
majority of the patients (92.1%) presented late with advanced GC (Stages III and IV). Lymph node 
and distant metastasis at the time of diagnosis was recorded in 31.9% and 29.3% of cases, 
